Amagma Therapeutics specializes in the discovery and development of antibody therapeutics against inflammatory diseases.
Amagma Therapeutics has raised $2.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2022.
Amagma Therapeutics's investors include Polaris Partners, Magnetic Ventures.
Amagma Therapeutics is headquartered in Waltham, United States.
Amagma Therapeutics specializes in the discovery and development of antibody therapeutics against inflammatory diseases.
Amagma Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amagma Therapeutics — Funding & Investors." VCBacked, June 1, 2022, https://www.vcbacked.co/company/amagma-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Amagma Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/amagma-therapeutics
{{cite web |title=Amagma Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amagma-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated